Saturday morning’s Career Development Forum, for preregistered attendees, will feature concurrent workshops focusing on clinical trials, grant writing, and career goals.

Findings from 10 studies, including IDEA, PREFERABLE-EFFECT, and POSITIVE, were presented Thursday during the second General Session of the 2023 SABCS®.

SABCS® Program Director Kate Lathrop, MD, shares a few highlights from Friday’s schedule to help you plan your day, including notable presentations, award lectures, and more.

Don’t miss Friday’s General Session abstract presentations and Poster Spotlight Session presentations, featuring research that has the potential to shape the future of breast cancer care.

Presenters on Tuesday discussed data and regulatory considerations for three recently approved targeted therapies—trastuzumab deruxtecan (T-Dxd), elacestrant, and capivasertib.

Two sessions on Friday afternoon will distill notable recent developments in breast cancer research and clinical practice into four hours of must-attend presentations.

Aditya Bardia, MD, MPH, will moderate a Friday afternoon session on the latest advances and strategies to target the estrogen receptor gene mutation in breast cancer, including novel drug therapies in development.

Prevention, early detection, and interception were the focus of the second Speccial Session on Tuesday at the 2023 SABCS®. Presenter Joanne Kotsopoulos, PhD, discussed use of hormones in patients with BRCA 1 and 2 mutations.